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A Recurrent Mosaic Mutation in SMO,
Encoding the Hedgehog Signal Transducer Smoothened,
Is the Major Cause of Curry-Jones Syndrome
Stephen R.F. Twigg,1 Robert B. Hufnagel,2 Kerry A. Miller,1 Yan Zhou,1 Simon J. McGowan,3
John Taylor,4,5 Jude Craft,4 Jenny C. Taylor,4,6 Stephanie L. Santoro,2 Taosheng Huang,2
Robert J. Hopkin,2 Angela F. Brady,7 Jill Clayton-Smith,8 Carol L. Clericuzio,9 Dorothy K. Grange,10
Leopold Groesser,11 Christian Hafner,11 Denise Horn,12 I. Karen Temple,13,14 William B. Dobyns,15
Cynthia J. Curry,16 Marilyn C. Jones,17 and Andrew O.M. Wilkie1,*
Curry-Jones syndrome (CJS) is a multisystem disorder characterized by patchy skin lesions, polysyndactyly, diverse cerebral mal-
formations, unicoronal craniosynostosis, iris colobomas, microphthalmia, and intestinal malrotation with myofibromas or hamarto-
mas. Cerebellar medulloblastoma has been described in a single affected individual; in another, biopsy of skin lesions showed features
of trichoblastoma. The combination of asymmetric clinical features, patchy skin manifestations, and neoplastic association previously
led to the suggestion that this could be amosaic condition, possibly involving hedgehog (Hh) signaling. Here, we show that CJS is caused
by recurrent somatic mosaicism for a nonsynonymous variant in SMO (c.1234C>T [p.Leu412Phe]), encoding smoothened (SMO),
a G-protein-coupled receptor that transduces Hh signaling. We identified eight mutation-positive individuals (two of whom had not
been reported previously) with highly similar phenotypes and demonstrated varying amounts of the mutant allele in different tissues.
We present detailed findings from brain MRI in three mutation-positive individuals. Somatic SMOmutations that result in constitutive
activation have been described in several tumors, including medulloblastoma, ameloblastoma, and basal cell carcinoma. Strikingly, the
most common of these mutations is the identical nonsynonymous variant encoding p.Leu412Phe. Furthermore, this substitution has
been shown to activate SMO in the absence of Hh signaling, providing an explanation for tumor development in CJS. This raises ther-
apeutic possibilities for using recently generated Hh-pathway inhibitors. In summary, our work uncovers the major genetic cause of CJS
and illustrates strategies for gene discovery in the context of low-level tissue-specific somatic mosaicism.The multiple-congenital-anomalies disorder Curry-Jones
syndrome (MIM: 601707) was first presented (in abstract
form) by Cynthia Curry and Marilyn Jones at the David
W. Smith Workshop on Malformations and Morphogen-
esis in 1987. These authors described two unrelated indi-
viduals with the shared features of unilateral coronal
craniosynostosis, cutaneous syndactyly, bilateral preaxial
polydactyly of the feet, and unusual streaky skin lesions.
Subsequently, the term Curry-Jones syndrome (CJS) was
applied to this condition.1,2
The first formal publication on CJS was by Temple et al.3
and included detailed clinical descriptions of the two orig-
inal subjects and three further unrelated individuals. Four
more simplex cases have since been added to the literature;
each affected individual had abnormal skin patches and
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 2016found in most individuals have included ectopic hair
growth, abnormalities of brain development, coloboma
and/or microphthalmia, coronal suture synostosis, cuta-
neous syndactyly, and intestinal malrotation and/or
obstruction (reviewed by Grange et al.6). Figures 1A–1D
show the major craniofacial, limb, and dermatological fea-
tures of CJS in a previously unreported individual (subject
8 in our series); MRI scans of three individuals (Figures 1E–
1G) illustrate the diversity of cerebral malformations
(described in more detail below). Mild intellectual
disability has been present in some individuals. In a single
individual, a desmoplastic medulloblastoma (World
Health Organization grade IV) of the right cerebellum,
found incidentally on a follow-up brain MRI scan at
17 months, was treated successfully by surgical resection,
chemotherapy, and radiotherapy.6 In two individuals,adcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK; 2Division of
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Figure 1. Clinical and Radiological Fea-
tures and Brain Imaging of Individuals
with CJS Caused by SMO Mutations
(A–D) Subject 8 at 2 years of age. (A) Facial
features show asymmetry, frontal bossing,
and scarring of the right eyelid. (B)
Computed-tomographic head scan at
7 months of age shows right coronal syn-
ostosis (arrow), a bifurcated sagittal suture,
and an anterior fontanellar bone. (C) The
right foot is medially deviated with a
duplicated hallux and partial cutaneous
syndactyly of digits 1–3. (D) The skin has
linear streaks of hypopigmentation with
atrophy; this was not visible at birth but
had developed by the age of 6 months.
(E–G) Brain MRI. (E) At 1 year, 5 months
old, subject 5 shows left-sided hemimega-
lencephaly with extensive cortical malfor-
mation (arrows) and ventriculomegaly
(asterisk). (F) At 3 months old, subject 6
shows subtle abnormalities of the gyri
and cortex (white arrows); a cyst in the
left thalamus (black arrow) connects
with a third-ventricle midline cyst. (G) At
1 day old, subject 8 shows a thin corpus
callosum, amildly hypoplastic cerebellum,
and an occipital cystic lesion pathologi-
cally confirmed to represent a lymphan-
giomatous malformation (white arrow).biopsies of active skin lesions were reported to show fea-
tures of either trichoblastoma6 or nevus sebaceus.3 In addi-
tion, odontogenic keratocysts have been found in one
individual, and lesions in the bowel, identified histologi-
cally as hamartomas or myofibromas, were reported in
three instances.3,6
The etiology of CJS was previously unknown, but three
clinical observations are relevant to hypotheses for causa-
tion. First, the nine previously reported individuals
comprised seven males and two females with similar dis-
ease severity, making an X-linked mutation unlikely. Sec-
ond, the sporadic origin of all individuals in association
with patchy skin lesions and asymmetric cranial findings
led Temple et al.3 to propose an underlying mosaic muta-
tion; however, Grange et al.6 favored a germline constitu-
tional mutation in view of the consistent presentation
and bilaterality of some of the other features. Third, the
occurrence of medulloblastoma in basal cell nevus syn-
drome (BCNS [MIM: 109400])—caused by mutations in
PTCH1 (MIM: 601309), which encodes the hedgehog
(Hh) receptor—as well as the overlapping cranial and
limb abnormalities found in disorders caused bymutations
in GLI3 (MIM: 165240), a downstream effector of the
Hh pathway, led Grange et al.6 to propose that perturba-
tion of Hh signaling could underlie CJS. However,
sequencing of PTCH1 and GLI3 in DNA obtained from
the blood of two individuals with CJS was normal.6 The
objective of the present work was to identify the causative
mutation(s) underlying CJS through whole-exome
sequencing (WES) by initially using an overlap strategy
in four individuals to pinpoint disease-causing variants
in the same gene.The AmericThe study was approved by Oxfordshire Research Ethics
Committee B (reference C02.143) and the Riverside
Research Ethics Committee (reference 09/H0706/20).
Participants or their parents provided informed, written
consent for genetic studies. Four of five samples initially
chosen for analysis were from CJS-affected individuals
reported by Temple et al.;3 these comprised both eyelid tis-
sue (sample 1-2, collected during an operation to repair a
malformed upper eyelid with ectopic hairs) and fibroblasts
from an affected skin biopsy (sample 1-4) from subject 1
(the individual originally described by Jones) and fibro-
blasts from affected skin of subjects 2 (sample 2-3) and 3
(sample 3-2), the latter of whom was the individual origi-
nally described by Curry. All fibroblast lines were analyzed
between three and five passages. An additional fifth sample
(4-1) was from the blood of subject 4, an unpublished indi-
vidual with features overlapping CJS. The clinical features
of these four individuals are summarized in Table 1.
After DNA extraction, we performed WES by using the
SeqCap EZ Human Exome Library v.2.0 (NimbleGen) on
a HiSeq 2000 (Illumina). Paired-end reads (100 bp) were
mapped to hs37d5 with Stampy v.1.0.22,7 and after
removal of artifacts, the average coverage was >303 over
82% of the exome. We used Platypus8 to call variants,
and assuming that CJS is caused by very rare autosomally
located variant(s), we prioritized the data by excluding
common variants present in either our in-house database
of solved cases or the NHLBI Exome Sequencing Project
(ESP) Exome Variant Server (later revised to the Exome
Aggregation Consortium [ExAC] Browser for reanalysis).
We compared across CJS individuals for hits in the same
gene. This analysis did not yield any genes with rare codingan Journal of Human Genetics 98, 1256–1265, June 2, 2016 1257
Table 1. Clinical Features of Subjects Diagnosed with CJS
Subject Gender Craniosynostosis Brain
Developmental
Attainment Eyes Skin
1 (SMOþ) F RC possible cyst in
trigone of right
ventricle
normal R amblyopia; skin
overgrowth
waxy, streaky
lesions; nevus
sebaceus
2 (SMOþ) M LC ACC; R HMEG;
R VMEG
mild delay normal raised, linear
white streaks;
normal biopsy
3 (SMOþ) M LC partial ACC;
asymmetric
dilated ventricles
mild ID; IQ < 70 L and R
microphthalmia;
R iris coloboma
raised, scar-like
pale lesions;
non-specific
biopsy
4 M bicoronal dilated ventricles;
choroid plexus
cyst
mild delay congenital
glaucoma;
secondary cataract
pigmentary
anomalies in
Blashko’s lines,
most notable on
limbs
5 (SMOþ) M none mild ACC;
L HMEG;
R VMEG and
PMG; occipital
meningocele;
Chiari I
malformation
mild to moderate
developmental
delay
L mild
colobomatous
microphthalmia
with unusually
shaped pupil
raised, linear
streaks (L arm and
leg, chin, and a
few other areas)
6 (SMOþ) M none partial ACC; MEG;
VMEG; Chiari I
malformation
mild delay (1–2
years behind
academically)
L and R iris
colobomas
hypopigmented
streaky lesions
7 (SMOþ) M none normal normal normal white, patchy skin
behind knees
8 (SMOþ) F RC partial ACC;
moderate cerebral
asymmetry
consistent with L
HMEG; PMG
mild delay normal;
dysmorphic R
eyelid
linear areas of
hypopigmented
skin atrophy
(extremities and
trunk)
9 F none ACC; dilated
ventricles;
macrocephaly
psychomotor
delay
bilateral
colobomas of iris,
retina, and
choroid;
strabismus;
nystagmus
hypopigmented
patch on trunk
10 (SMOþ) F LC ACC; abnormal
cortical dysplasia
of R perirolandic
region
psychomotor
delay
corneal clouding;
eyelid irregularity
and ectopic hairs
mostly R-sided
hypo- and
hyperpigmented
swirling skin
lesions; increased
hair in
hyperpigmented
areas
Abbreviations are as follows: F, female; M, male; LC, left coronal; RC, right coronal; R, right; L, left; ACC, agenesis of the corpus callosum; MEG, megalencephaly;
HMEG, hemimegalencephaly; VMEG, ventriculomegaly; PMG, polymicrogyria; ID, intellectual disability; GI, gastrointestinal; H, hands; and F, feet.
(Table continued on next page)
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Hair GI Tract
Cutaneous
Syndactyly Polydactyly Tumors Other
Previously
Reported?
ectopic patch of
hair above R eye
GI bleeding;
chronic
constipation
L 1/2/3 (H);
R 2/3 (H)
R trifid hallux – asymmetric face case 4 in
Temple et al.3
ectopic patch of
hair near eyes
intestinal
obstruction
L 2/3 (H), 3/4 (F);
R 2/3/4 (H), 2/3 (F)
L and R broad
thumbs, preaxial
polydactyly (F)
myofibromas of
large bowel
lip pits; seizures case 1 in
Temple et al.3
ectopic patch
of hair above R eye
esophageal
dysmotility
L and R
1/2/3/4 (H)
L and R bifid
halluces
– asymmetric face;
fused central
incisor;
oligodontia;
freckled areas on
soles of feet;
esophageal
dysmotility
case 3 in
Temple et al.3
chaotic hair
patterning of
lateral portions of
eyebrows
diarrheal episodes L and R 2/3/4 (F) broad halluces – cleft palate no
ectopic hair on
cheek
malrotation;
intestinal
pseudo-obstruction;
chronic
constipation;
subtotal
colectomy for
volvulus and
obstipation
L 1/2/3/4 (H),
3/4 (F); R 2/3 (H),
3/4 (F)
L and R preaxial
polydactyly (F);
R thumb nubbin
desmoplastic
medulloblastoma
of cerebellum;
odontogenic
keratocysts;
benign colonic
polyps and
smooth muscle
hamartoma
large anterior
fontanelle; lip pits
patient 2 in
Grange et al.6
ectopic patch of
hair near eyes
malrotation L 1/2/3 (H),
1/2 (F); R 2/3 (H)
L and R preaxial
polydactyly (H),
preaxial
polydactyly (F)
trichoblastoma;
smooth muscle
hamartomas of GI
tract
mildly asymmetric
face; lip pit
patient 1 in
Grange et al.6
abnormal hair
growth on
shoulders and
limbs
normal R 1/2/3/4 (H) L and R preaxial
polydactyly (F);
R: broad thumb
– plagiocephaly Thomas et al.5
– malrotation;
intermittent
pseudo-obstruction;
serosal nodules in
the appendix,
mesentery,
and duodenum
L and R variable
1/2/3 (H and F)
L and R duplicated
thumbs and
halluces
scalp
lymphangiomas:
benign
hamartomatous
lesion with
features of
lymphangioma
and nevus
sebaceus; serosal
hamartomas in
duodenum,
appendix, and
mesentery
accessory bone
at anterior
fontanelle;
wormian bones of
L posterior skull;
L leg longer than
R; lumbar scoliosis
no
high frontal
hairline
chronic
constipation
L and R 3/4 (H) L and R duplicated
thumbs and
halluces
lipomyelomeningocele rudimentary sacral
vertebrae
no
ectopic hairs;
hirsutism
dysmotility;
malrotation;
multiple
hamartomas of
small intestine
R 1/2 (H) L and R duplicated
thumbs and
halluces
multiple
mesenteric
hamartomas with
smooth muscle
bundles with
inter-myenteric
ganglia
grade 2
hydronephrosis
no
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Figure 2. Identification of a Mosaic SMO c.1234C>T Mutation
(A) GBrowse10 visualization of exome sequence data from two tissues of subject 1. The upper panel shows the location of SMO in
chromosomal region 7q32.1, and the middle and lower panels display a 144 bp alignment of sequencing reads aligned to exon 6
and the following intron; bases that match the reference sequence are boxed in black, and variants are in red. The red arrows indicate
the position of the c.1234C>T mutation (indicated by a ‘‘t’’ within a red box), which was present in 53% of reads in tissue 1-4 (middle
panel; not all reads are shown) but only in 5% of reads in tissue 1-2 (lower panel). Flanking heterozygous SNPs are indicated by black
arrows.
(B) Dideoxy-sequence traces for the c.1234C>T mutation. (Top) In sample 1-4, the mutation appears to be present in the heterozygous
state, and there is no evidence of dilution by non-mutant cells (red arrow). (Middle) In samples 1-2 and 2-3, a small proportion of the
mutant c.1234Tallele is suspected to be present on the basis of both the presence of a small T peak and the reduced relative height of the
normal C peak (pink arrows; compare with the control at bottom). By contrast, themutation does not appear to be present in samples 3-2
and 4-1.variants shared by three or four individuals, and only three
genes had rare coding variants shared by two individuals,
but none were strong candidates (Table S1).
As an alternative approach, we compared the data from
the two tissues separately sequenced from subject 1, given
that mosaicism for a pathogenic variant could be detect-
able through differences in allele frequencies between da-
tasets. Variants were ranked according to a somatic p value
score generated by the software tool MiG,9 which
compares variant and reference read counts between two
datasets (Figure S1). The top hit was a nonsynonymous
substitution in SMO (MIM: 601500; GenBank:
NM_005631.4): c.1234C>T (p.Leu412Phe), present in 44
of 83 sequence reads from fibroblast sample 1-4. Notably,
this variant was not called in the exome data from eyelid
sample 1-2, although a low level of the same variant (2 of
40 sequence reads) was apparent on manual examination
of the reads (Figure 2A). The fortuitous presence of two1260 The American Journal of Human Genetics 98, 1256–1265, Juneheterozygous flanking SNPs (rs2228617 and rs2735842;
dbSNP137) in this individual enabled the two SMO alleles
to be easily distinguished. We noted that when sequence
reads included both the c.1234 position and one of the
flanking SNPs, the mutant c.1234T reads were always in
ciswith the variant allele of the SNP in both samples. How-
ever, for the eyelid sample 1-2, the converse was not true,
supporting the conclusion that the c.1234C>T mutation
was mosaic in this sample (see Figure 2). SMO encodes
smoothened (SMO), a frizzled G-protein-coupled receptor
that plays a key role in transducing Hh signaling. Hh bind-
ing relieves patched-mediated suppression of SMO to allow
transduction of the signal, probably mediated by confor-
mational changes within the 7-transmembrane bundle.11
Hence, the variant matched all three criteria (autosomal,
mosaic, and affecting Hh signaling) for the characteristics
of a candidate CJS-associated gene on the basis of clinical
deduction.3,6 Adding further weight to the conclusion2, 2016
Figure 3. Quantification of Tissue Mosaicism for the SMO
c.1234C>T Mutation
Plot of deep sequencing data shows the proportion of the mutant
c.1234Tallele in tissue samples collected from subjects 1–9. Similar
tissue sources are grouped by color, indicated by a colored rect-
angle below the corresponding sample number. Individual tissue
identifications along the horizontal axis correspond to the
numbering listed in Table S2.that this was the pathogenic variant, the Catalogue of
Somatic Mutations in Cancer (COSMIC) revealed that
SMO c.1234C>T is a known mutation hotspot in
multiple tumor types (discussed further below). Dideoxy-
sequencing of SMO exon 6 in sample 1-4 confirmed the
presence of the C>T variant in an apparently heterozygous
state, but the mutant peak was barely visible in sample 1-2
(Figure 2B).
In light of this finding, we scrutinized the exome
sequence data for SMO from the other three CJS individ-
uals in greater detail. The identical c.1234C>T variant
was present in 2.7% (6 of 219) of reads from sample 2-3
(Figure S2) but was absent in the other two samples (0 of
57 reads from sample 3-2 and 0 of 179 reads from sample
4-1); no other suspicious SMO variant was detected in the
exome sequences of subjects 3 or 4.
To gather further evidence that mosaic SMO mutations
cause CJS, we collected and analyzed additional tissue
samples from subjects 1–4 together with a further six indi-
viduals with CJS (subjects 5 and 6 reported by Grange
et al.,6 subject 7 reported by Thomas et al.,5 and three un-
published individuals; clinical features are summarized in
Table 1). Material from affected regions was prioritized
and included archival formalin-fixed paraffin-embedded
(FFPE) sections, such as those illustrated for affected skin
and gut hamartoma in Grange et al.6 (Table S2). We used
the Ion Torrent PGM to perform deep sequencing of SMO
exon 6 in a total of 37 different tissue samples from the
ten CJS subjects (including the previously sequenced
samples) and three control samples. Table S3 lists the
primer sequences and conditions used for SMO (GenBank:
NG_023340.1) amplification and sequencing. Deep
sequencing of DNA from subject 1 confirmed a ~50% fre-
quency for c.1234C>T in fibroblast sample 1-4 and
showed that the variant was present at an 11% frequency
in eyelid sample 1-2 (Figure 3 and Table S2). Surprisingly,
we did not identify any mutant c.1234T alleles in theThe Americaffected skin sample (1-3) from which the fibroblasts
constituting sample 1-4 were derived, possibly indicating
positive selection of mutant cells during growth in culture.
In subject 2, the exome finding suggesting that the tested
sample (2-3) was positive for an SMO mutation was vali-
dated, and c.1234C>T variant frequencies ranging from
4%–25%were detected in three of five samples, confirming
mosaicism for the identical SMO mutation in this
individual.
Deep sequencing of SMO in the samples used for exome
sequencing (3-2 and 4-1) confirmed that the c.1234C>T
mutation was essentially undetectable, given that the
data were indistinguishable (by Fisher’s exact test) from
the control samples (Table S2). However, a new skin-biopsy
sample from subject 3 was positive (14%), and a low level
(1.6%) was detected in saliva. Furthermore, five of the six
additional CJS individuals (subjects 5–8 and 10) were also
mosaic for c.1234C>T (Figure 3 and Table S2). FFPE mate-
rial from an occipital meningocele and cerebellar medullo-
blastoma were available from subject 5 (corresponding to
patient 2 in Grange et al.6), and analysis showed relatively
high levels of mosaicism for the c.1234T allele at 20% and
43%, respectively. Similarly, the abdominal smoothmuscle
tumor sections from subject 6 (patient 1 in Grange et al.;6
samples 6-3 and 6-4) contained the c.1234T allele at 35%–
37%. In subject 7, a mildly affected individual,5 we
detected c.1234T at 3%–4% in skin (sample 7-1, taken
from a hairy area of the inner leg) and associated fibro-
blasts (7-2), as well as a femoral bone marrow sample
(7-5, 1%). Finally, we identified the c.1234T variant in sam-
ples from two unpublished individuals, subjects 8 (Figures
1A–1D and 1G and Supplemental Note) and 10 (Table 1).
FFPE samples from the colon (8-2) and cecum (8-3)
collected from subject 8 during investigation of intestinal
malrotation and mesenteric masses (which contained ha-
martomatous nodules consisting of disorganized bundles
of mature smooth muscle intermixed with nerve fibers
and ganglion cells) contained the c.1234T allele at levels
of 8%–9%. In subject 10, an affected skin sample and
derived fibroblasts contained c.1234T at 33% and 16%,
respectively (Figure 3).
In total, we identified the identical SMO c.1234C>T
mutation in tissues from eight unrelated CJS-affected indi-
viduals, including the two originally described by Curry
and Jones. In all but one sample (1-4, in which the muta-
tion was originally identified by exome sequencing), the
c.1234T allele was present at a level substantially below
50%, indicating tissue mosaicism. Importantly for diag-
nosis, we had the greatest success in detecting the muta-
tion in affected tissues obtained by invasive procedures.
The mutation was not reliably detected in blood samples
from three mutation-positive individuals (levels of
c.1234T ranged from 0.03% to 0.5%, which we believe is
below the threshold for clinical diagnosis [1%]; Figure 3
and Table S2). We had greater success with saliva samples
(mean ¼ 3.6% and range ¼ 0.11%–7.1% in four muta-
tion-positive individuals), but in every individual, aan Journal of Human Genetics 98, 1256–1265, June 2, 2016 1261
different tissue sample showed a higher mutation level
(Figure 3 and Table S2). This suggests that the optimum
strategy for detecting mosaic mutations in CJS is to sample
affected skin and tissue from internal organs if available. In
subjects 4 and 9, from whom only blood and saliva sam-
ples were available, levels of the c.1234C>T mutation
were 0.11% or lower. Although the results for some
samples differed from those of control samples on formal
statistical testing, they were deemed indeterminate for
clinical purposes. Deep sequencing of the entire SMO
coding region did not identify any alternative variants
(data not shown). Analysis of tissue samples from affected
regions would be required for determining whether these
two individuals in fact carry the canonical mutation or
have a distinct genetic basis for their phenotype.
The finding of widespread mosaicism in CJS suggests
that it arises post-zygotically early during embryonic devel-
opment. A somewhat later acquisition of the mutation is
predicted to cause isolated pathology of individual organs,
so we explored this possibility in the context of the skin.
We performed deep sequencing of SMO in 14 isolated tri-
choblastoma samples and a single nevus sebaceus sample,
given that analysis of skin biopsies from subjects 1 and 6
had previously demonstrated nevus sebaceus3 and
trichoblastoma,6 respectively. Although we detected rare
SNPs, we did not find potentially pathological variants
(Table S4).
We sought to further define the neuroanatomical fea-
tures of CJS by reviewing recent MRI scans of three muta-
tion-positive individuals (subjects 5, 6, and 8). A diverse
range of phenotypes were present in this small sample;
prominent features are illustrated in Figures 1E–1G, and
the complete phenotype is summarized in Table S5 and
presented in Figure S3. Abnormal findings included hemi-
megalencephaly (HMEG) with cortical dysplasia, white-
matter abnormalities and polymicrogyria, abnormalities
of the corpus callosum, ventriculomegaly, occipital menin-
gocele, and a Chiari type I malformation. Given the
phenotypic overlap with isolated megalencephaly and/or
HMEG and the previous observation of associated muta-
tions in components of the PI3K-AKT pathway,12–14 it
would be of interest to test such mutation-negative brain
samples for variants in SMO.
Although no constitutional mutations in SMO have pre-
viously been described, several hotspots of somatic muta-
tion are evident in COSMIC, and it is striking that the
most frequent of these is the identical c.1234C>T transi-
tion (note, this does not occur in the context of a CpG
dinucleotide, so intrinsic hypermutability15 is not pre-
dicted). Notably, the SMO c.1234C>T mutation has been
identified in ameloblastoma,16,17 medulloblastoma,18,19
meningioma,20,21 and basal cell carcinoma (BCC);22,23
moreover, it has been reported as the oncogenic driver in
some of these tumors.16,23 The altered amino acid
Leu412 locates to transmembrane helix 5 of SMO within
one of three pivot regions that, by analogy with the b2
adrenergic receptor,24 are likely to have a key role in the1262 The American Journal of Human Genetics 98, 1256–1265, Juneconformational changes required for receptor activation.
Supporting this, the presence ofmutant p.Leu412Phe leads
to constitutive activation in the absence of Hh ligand in
Smo/ mouse embryonic fibroblasts16,22 and increased
cell proliferation in ameloblast-lineage cells.16
Vertebrates have three Hh ligands, sonic hedgehog
(SHH), desert hedgehog (DHH), and Indian hedgehog
(IHH), which remove inhibition of SMO by binding to
the receptor patched (encoded by PTCH1 or PTCH2
[MIM: 603673]). Downstream effectors of Hh signal trans-
duction, notably the transcription factors GLI2 and GLI3,
are normally tethered by SUFU (suppressor of fused
homolog) at the base of the primary cilium, where they
are proteolytically processed to repressor forms (GLI2-R
and GLI3-R, respectively). SMO activation leads to KIF7-
dependent translocation toward the tip of the primary
cilium and to transport of full-length activated GLI pro-
teins (GLI2-A and GLI3-A) into the nucleus, enabling tran-
scriptional activation (reviewed by Briscoe and Therond,25
McCabe and Leahy,26 and Arensdorf et al.27). Activation of
the PI3K-AKT-mTOR and/or PKA pathways can indepen-
dently lead to GLI activation, indicating the potential for
significant cross-talk with the Hh pathway.28 Constitu-
tional mutations that mimic the consequences of Hh
signal activation include loss-of-function mutations in
negative regulators acting at multiple stages of the Hh
pathway, such as RAB23 (associated with Carpenter
syndrome [MIM: 606144]),29 PTCH130–32 and SUFU33,34
(associated with BCNS), KIF7 (associated with acrocallosal
syndrome),35 and GLI3 (associated with Greig cephalopo-
lysyndactyly).36,37 In addition, regulatory mutations in
IHH (MIM: 600726) cause Philadelphia craniosynosto-
sis.38 Reflecting the net consequence of excessive Hh signal
transduction, several clinical features of CJS overlap those
of the above disorders, as previously noted.6 These include
craniosynostosis39 in both Carpenter and Philadelphia
craniosynostosis syndromes, preaxial polydactyly in Greig
and Carpenter syndromes,40 cerebral malformations in
acrocallosal syndrome,35 and odontogenic keratocysts
and skin involvement in BCNS.41 We also note overlap
between the cerebral features and mosaic activation of
components of the PI3K-AKT-mTOR pathway, such as in
Proteus syndrome (MIM: 164730), fibroadipose hyperpla-
sia and CLOVES syndrome (MIM: 612918), and HMEG
(reviewed in Keppler-Noreuil et al.,12 Hevner,13 and Jansen
et al.14). To our knowledge, abnormalities of the bowel
have not previously been highlighted as a frequent feature
of disorders associated with activation of Hh signaling, but
they appear to be common in CJS (e.g., malrotation and
myofibromas or hamartomas). These bowel abnormalities
are consistent with the documented role of murine SHH
and IHH, produced by the endodermal epithelium, as pri-
mary factors in the patterning and organogenesis of the
gut,42 where Hh signaling from the endoderm controls
growth of the adjacent mesenchyme.43 Mouse embryos
in which Smo is deleted from the gut mesenchyme have
severely reduced proliferation and differentiation of the2, 2016
intestinal mesenchyme and a reduced number of smooth
muscle cells and enteric neurons.44
Given the observed association between CJS and
neoplastic diseases (trichoblastoma and cerebellar medul-
loblastoma), a particularly important consequence of iden-
tifying the activating p.Leu412Phe substitution in SMO
concerns the potential pharmacotherapeutic implications
for management of affected individuals. Recently, there
has been considerable interest in developing SMO inhibi-
tors to reduce activation of the Hh pathway (reviewed by
Arensdorf et al.27). For example, vismodegib is a clinically
approved SMO inhibitor that contacts the extracellular
domain and ligand-binding pocket. Interestingly, in a
recent report of a subject with segmental BCNS associated
with the identical SMO p.Leu412Phe substitution,45 treat-
ment with vismodegib for 4 months led to cessation of the
appearance of new lesions and shrinkage of some existing
BCCs. However, other reports have suggested that the
p.Leu412Phe substitution confers resistance to vismode-
gib, supporting a role for Leu412 in autoinhibition and/or
structural stability.22,23 This suggests that in CJS-associated
tumors, the use of additional agents, such as arsenic
trioxide or other more-specific GLI inhibitors or PI3K-
AKT-mTOR inhibitors, that act at later stages of the Hh
signal-transduction pathway should be explored,33 and
indeed there is evidence that this approach can be effective
against p.Leu412Phe mutants.16,22
In summary, these data show that the major phenotypic
features of CJS are attributable to excessive activation of
Hh signaling owing to a specific c.1234C>T (p.Leu412Phe)
somatic mutation. The finding that all eight mutation-pos-
itive individuals are mosaic might indicate that constitu-
tional mutations are not compatible with life, as is true
for several other sporadic autosomal disorders.46 Themuta-
tion is likely to be associated with a spectrum of negative
and positive selective consequences during organismal
growth and homeostasis, depending on cell type, which
most likely explains the apparent evolution of skin lesions
and low mutation levels in blood (negative selection) and
the predisposition to tumorigenesis (positive selection).
The association between segmental BCNS and SMO
p.Leu412Phe in a recent report45 is compatible with a later
occurrence of the somatic mutation during development
than in subjects with the classical CJS phenotype.Supplemental Data
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